sunvozertinib (ZEGFROVY)

Indications

• treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations & disease progression on or after platinum-based chemotherapy.

Contraindications

• pregnancy
• breast feedimg

Dosage

• 200 mg orally once daily taken with food.

Tablets: 150 mg & 200 mg.

Adverse effects

• >= 20%
  • diarrhea, rash, decreased appetite, stomatitis, fatigue, nausea, paronychia, vomiting, constipation, musculoskeletal pain, pruritus, dry skin, urinary tract infection, abdominal pain, weight loss
• interstitial lung disease/pneumonitis
• keratitis
• laboratory abnormalities >= 2%
  • lymphopenia, increased lipase, decreased hemoglobin, increased amylase, increased creatine kinase, neutropenia, hypokalemia, increased serum AST, increased serum ALT, hyponatremia, increased serum magnesium, increased alkaline phosphatase

Drug interactions

• strong CYP3A Inhibitors
• strong or moderate CYP3A Inducers
• P-gp or BCRP Substrates
• hormonal contraceptics

Mechanism of action

• inhibits EGFR exon 20 insertion mutations at similar concentrations as wild-type EGFR

More general terms

• small inhibitory antineoplastic agent (ib drug)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=139377809
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=139377763